Best practice in the management of mild-to-moderately active ulcerative colitis and achieving maintenance of remission using mesalazine

European Journal of Gastroenterology and Hepatology

Volumn 22, Issue 8, 2010, Pages 912-916

  Munkholm, Pia ^a   Michetti, Pierre ^c   Probert, Chris S ^d   Elkjaer, Margarita ^b   Marteau, Philippe ^e  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^c LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^d Bristol Hospital in Bristol   (United Kingdom)

^e UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

clinical practice; cost; mesalazine; quality of life; remission; ulcerative colitis

Indexed keywords

MESALAZINE; PREDNISOLONE; NONSTEROID ANTIINFLAMMATORY AGENT;

COST EFFECTIVENESS ANALYSIS; DOSE RESPONSE; DRUG COST; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; HUMAN; MAINTENANCE THERAPY; PATIENT COMPLIANCE; PATIENT SATISFACTION; PRIORITY JOURNAL; PROCTITIS; REMISSION; REVIEW; ULCERATIVE COLITIS; COLITIS, ULCERATIVE; ECONOMICS; HEALTH CARE COST; PATIENT PREFERENCE; QUALITY OF LIFE; TREATMENT OUTCOME;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; COLITIS, ULCERATIVE; HEALTH CARE COSTS; HUMANS; MESALAMINE; PATIENT COMPLIANCE; PATIENT PREFERENCE; PROCTITIS; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 77955193872     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/MEG.0b013e32833944bf     Document Type: Review

References (47)

1. Langholz E, Munkholm P, Davidsen M, Binder V. Course of ulcerative colitis: analysis of changes in disease over years. Gastroenterology 1994; 107:3-11.
2. Roseth AG, Aadland E, Grzyb K. Normalization of faecal calprotectin: a predictor of mucosal healing in patients with inflammatory bowel disease. Scand J Gastroenterol 2004; 39:1017-1020.
3. Reinisch W, Sandborn WJ, Bala M, Yan S, Feagan BG, Rutgeerts P, et al. Response and remission are associated with improved quality of life, employment and disability status, hours worked, and productivity of patients with ulcerative colitis. Inflamm Bowel Dis 2007; 13:1135-1140.
4. Van der Eijk I, Vlachonikolis I, Munkholm P, Nijman J, Bernklev T, Politi P, et al.; on behalf of the EC-IBD Study Group. The role of quality of care in healthrelated quality of life in patients with IBD. Inflamm Bowel Dis 2004; 10:392-398.
5. Elkjaer M, Moser G, Reinisch W, Durovicova D, Lukas M, Vucelic B, et al. IBD patients need in health quality of care ECCO consensus. J Crohn's Colitis 2008; 2:181-188.
6. Westwood N, Travis SP. Review article: what do patients with inflammatory bowel disease want for their clinical management? Aliment Pharmacol Ther 2008; 26 (Suppl 1):1-8.
7. Ansari R, Attari F, Razjouyan H, Etemadi A, Amjadi H, Merat S, Malekzadeh R. Ulcerative colitis and irritable bowel syndrome: relationships with quality of life. Eur J Gastroenterol Hepatol 2008; 20:46-50.
8. Ghosh S, Mitchell R. Impact of inflammatory bowel disease impact on quality of life: results of the European Federation of Crohn's and Ulcerative Colitis Associations (EFCCA) patient survey. J Crohn's Colitis 2007; 1:1-10.
9. Travis SPL, Stange EF, Lemann M, Öresland T, Chowers Y, Forbes A, et al. European evidence-based consensus on the management of ulcerative colitis: current management. J Crohn's Colitis 2008; 2:24-62. (Pubitemid 351179488)
10. Marshall JK, Irvine EJ. Putting rectal 5-aminosalicylic acid in its place: the role in distal ulcerative colitis. Am J Gastroenterol 2000; 95:1628-1636.
11. Hanauer SB; The US PENTASA Enema Study Group. Dose-ranging study of mesalamine (PENTASA) enemas in the treatment of acute ulcerative proctosigmoiditis: results of a multicentered placebo-controlled trial. Inflamm Bowel Dis 1998; 4:79-83.
12. Campieri M, Gionchetti P, Belluzzi A, Brignola C, Tampieri M, Iannone P, et al.Optimum dosage of 5-aminosalicylic acid as rectal enemas in patients with active ulcerative colitis. Gut 1991; 32:929-931.
13. Cohen RD, Woseth DM, Thisted RA, Hanauer SB. A meta-analysis and overview of the literature on treatment options for left-sided ulcerative colitis and ulcerative proctitis. Am J Gastroenterol 2000; 95:1263-1276.
14. Marshall JK, Irvine EJ. Rectal corticosteroids versus alternative treatments in ulcerative colitis: a meta-analysis. Gut 1997; 40:775-781.
15. Manguso F, Balzano A. Meta-analysis: the efficacy of rectal beclomethasone dipropionate vs. 5-aminosalicylic acid in mild to moderate distal ulcerative colitis. Aliment Pharmacol Ther 2007; 26:21-29.
16. Lee FI, Jewell DP, Mani V, Keighley MR, Kingston RD, Record CO, et al. A randomised trial comparing mesalazine and prednisolone foam enemas in patients with acute distal ulcerative colitis. Gut 1996; 38:229-233.
17. Connolly MP, Poole CD, Currie CJ, Marteau P, Nielsen SK. Quality of life improvements attributed to combination therapy with oral and topical mesalazine in mild-to-moderately active ulcerative colitis. Digestion 2009; 80:241-246.
18. Marteau P, Probert CS, Lindgren S, Gassul M, Tan TG, Dignass A, et al. Combined oral and enema treatment with Pentasa (mesalazine) is superi or to oral therapy alone in patients with extensive mild/moderate active ulcerative colitis: a randomised, double blind, placebo controlled study. Gut 2005; 54:960-965.
19. Safdi M, DeMicco M, Sninsky C, Banks P,Wruble L, Deren J, et al. A doubleblind comparison of oral versus rectal mesalamine versus combination therapy in the treatment of distal ulcerative colitis. Am J Gastroenterol 1997; 92:1867-1871.
20. Hanauer SB, Sandborn WJ, Dallaire C, Archambault A, Yacyshyn B, Yeh C, et al. Delayed-release oral mesalamine 4.8 g/day (800mg tablets) compared to 2.4 g/day (400mg tablets) for the treatment of mildly to moderately active ulcerative colitis: The ASCEND I trial. Can J Gastroenterol 2007; 21:827-834.
21. Hanauer SB, Sandborn WJ, Kornbluth A, Katz S, Safdi M,Woogen S, et al. Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial. Am J Gastroenterol 2005; 100:2478-2485.
22. Lichtenstein GR, Kamm MA, Boddu P, Gubergrits N, Lyne A, Butler T, et al. Effect of once or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis. Clin Gastroenterol Hepatol 2007; 5:95-102.
23. Kamm MA, Lichtenstein GR, Sandborn WJ, Schreiber S, Lees K, Barrett K, et al. Randomised trial of once- or twice-daily MMX mesalazine for maintenance of remission in ulcerative colitis. Gut 2008; 57:893-902.
24. Kane S, Huo D, Magnanti K. A pilot feasibility study of once daily versus conventional dosing mesalamine for maintenance of ulcerative colitis. Clin Gastroenterol Hepatol 2003; 1:170-173.
25. Prantera C, Kohn A, Campieri M, Caprilli R, Cottone M, Pallone F, et al. Clinical trial: ulcerative colitis maintenance treatment with 5-ASA: a 1-year, randomized multicentre study comparing MMX with Asacol. Aliment Pharmacol Ther 2009; 30:908-918.
26. Kruis W, Jonaitis L, Pokrotnieks J, Acute G, Mikhailova T, Horynski M, et al. Once daily 3 g mesalamine is the optimal dose for maintaining clinical remission in ulcerative colitis: a double-blind, double-dummy, randomized, controlled, dose-ranging study. Gastroenterology 2008; 134 (4 Suppl 1):A-489.
27. Hanauer SB, Good LI, Goodman MW, Pizinger RJ, Strum WB, Lyss C, et al. Long-term use of mesalamine (Rowasa) suppositories in remission maintenance of ulcerative proctitis. Am J Gastroenterol 2000; 95:1749-1754.
28. Marteau P, Crand J, Foucault M, Rambaud J. Use of mesalazine slow release suppositories 1 g three times per week to maintain remission of ulcerative proctitis: a randomised double blind placebo controlled multicentre study. Gut 1998; 42:195-199.
29. Mantzaris GJ, Hatzis A, Petraki K, Spiliadi C, Triantaphyllou G. Intermittent therapy with high-dose 5-aminosalicylic acid enemas maintains remission in ulcerative proctitis and proctosigmoiditis. Dis Colon Rectum 1994; 37:58-62.
30. Piodi LP, Ulivieri FM, Cermesoni L, Cesana BM. Long-term intermittent treatment with low-dose 5-aminosalicylic enemas is efficacious for remission maintenance in ulcerative colitis. Scand J Gastroenterol 2004; 39:154-157.
31. Orchard T, Probert CS, Keshav S. Review article: maintenance therapy in patients with ulcerative colitis. Aliment Pharmacol Ther 2006; 24:17-22.
32. Paoluzi OA, Iacopini F, Pica R, Crispino P, Marcheggiano A, Consolazio A, et al. Comparison of two different daily dosages (2.4 vs. 1.2 g) of oral mesalazine in maintenance of remission in ulcerative colitis patients: 1-year follow-up study. Aliment Pharmacol Ther 2005; 21:1111-1119.
33. Dignass AU, Bokemeyer B, Adamek H, Mross M, Vinter-Jensen L, Börner N, et al. Mesalamine once daily is more effective than twice daily in patients with quiescent ulcerative colitis. Clin Gastroenterol Hepatol 2009; 7:762-769.
34. Kane S, Huo D, Aikens J, Hanauer S. Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis. Am J Med 2003; 114:39-43.
35. Shale MJ, Riley SA. Studies of compliance with delayed-release mesalazine therapy in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2003; 18:191-198.
36. Velayos FS, Terdiman JP, Walsh JM. Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: a systematic review and meta-analysis of observational studies. Am J Gastroenteroloy 2005; 100:1345-1353.
37. Loftus EV Jr. A practical perspective on ulcerative colitis: patient's needs from aminosalicylate therapies. Inflamm Bowel Dis 2006; 12:1107-1113.
38. Boutron-Ruault MC, Seksik P, Tucat G, Dolléans MC, Idier I, Marteau-Baudin A, et al. Factors associated with nonadherence to medical therapy in inflammatory bowel disease: The TOTEM survey on 1145 patients in France. Abstract P1084, UEGW 2009.
39. Elkjaer M, Burisch J, Avnstrøm S, Lynge E, Munkholm P. Development of a Web-based concept for patients with ulcerative colitis and 5-aminosalicylic acid treatment. Eur J Gastroenterol Hepatol 2009; 12:2326-2331.
40. Elkjaer M, Burisch J, Voxen Hansen V, Deibjerg Kristensen B, Slott Jensen JK, Munkholm P. A new rapid home test for faecal calprotectin in ulcerative colitis. Aliment Pharmacol Ther 2009; 31:323-330.
41. NICE. Infliximab for subacute manifestations of ulcerative colitis. NICE guidance TA140. 23 April 2008.
42. Kane SV, Brixner D, Rubin DT, Sewitch MJ. The challenge of compliance and persistence: focus on ulcerative colitis. J Manag Care Pharm 2008; 14 (Suppl 1):S1-S14.
43. Connolly M, Nielsen SK, Currie CJ, Poole C, Travis SPL. An economic evaluation comparing once daily with twice daily mesalazine for maintaining remission based on results from a randomised controlled clinical trial. J Crohn's Colitis 2009; 3:32-37.
44. Buckland A, Bodger K. The cost-utility of high dose oral mesalazine for moderately active ulcerative colitis. Aliment Pharmacol Ther 2008; 28:1287-1296.
45. Sandborn WJ, Regula J, Feagan BG, Belousova E, Jojic N, Lukas M, et al. Delayed-release oral mesalamine 4.8 g/day (800-mg tablet) is effective for patients with moderately active ulcerative colitis. Gastroenterology 2009; 137:1934-1943.
46. Connolly MP, Nielsen SK, Currie CJ, Marteau P, Probert CSJ, Travis SPL. An economic evaluation comparing concomitant oral and topical mesalazine versus oral mesalazine alone in mild-to-moderately active ulcerative colitis based on results from randomised controlled trial. J Crohn's Colitis 2009; 3:168-174.
47. Higgins PDR, Rubin DT, Kaulback K, Schoenfield PS, Kane SV. Systematic review: impact of non-adherence to 5-ASA products on the frequency and cost of ulcerative colitis flares. Aliment Pharmacol Ther 2009; 29:247-257